Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Global Brain Health topic
No spam. Unsubscribe anytime.
House Foreign Affairs subcommittee hearing spotlights push for U.S. 'global brain health' legislation
Summary
Witnesses told a House Foreign Affairs subcommittee that Alzheimer’s, autism and childhood brain conditions require a coordinated U.S. global strategy; lawmakers said they will press legislation authorizing U.S. participation in multinational research and capacity‑building efforts.
Chairman Chris Smith convened a House Foreign Affairs subcommittee hearing to press for expanded U.S. leadership on ‘global brain health,’ saying persistent international gaps in research, care and prevention require new congressional action.
Smith opened the session by tracing a string of unmet global needs — from Alzheimer’s and other dementias to autism and hydrocephalus — and said he will reintroduce and press for a global brain health bill in the next Congress. “I have introduced my bill, the global brain health bill… and have not been able to get it passed, but I'm absolutely determined that in the next Congress, we will see it come to fruition,” he said.
Witnesses recommended a combination of increased research funding, partnerships with multilateral initiatives and scaled implementation of proven public‑health measures. Dr. Gladys Maestro, director of the Rio Grande Valley Alzheimer’s Disease Resource Center for Minority Aging Research, said biomarkers and recent FDA approvals for some therapies create an opportunity to shift toward earlier detection and prevention but warned the treatments are not cures. “They do work… they clean it. But if there is too much amyloid already, then there are already other changes in the brain,” Maestro said, arguing that earlier detection must be matched with a global research strategy that includes underrepresented populations.
Several witnesses supported a statutory authorization the transcript identifies as the GAIN Act, which would allow U.S. participation in and contributions to the Davos Alzheimer’s Collaborative (DAC). Dr. Barra (who opened the panel) described DAC as “the first global alliance of governments, nonprofits, academia, and the private sector” and said the collaborative aims to link and scale existing efforts across sectors.
Panelists also urged that U.S. investments emphasize capacity building and implementation as much as basic science. Dr. Yashoda H. Grama, associate director for research at the Eleanor Cook (transcript: "Eleanor Crook") Foundation, said cost‑effective nutrition and prenatal interventions (including multiple micronutrient supplements and breastfeeding support) can substantially improve early brain development if delivered at scale. “We have proven, cost‑effective solutions ready to be scaled,” she said, and described a roadmap to deliver improved prenatal supplements to high‑burden countries.
Lawmakers pressed witnesses on how to coordinate USAID, HHS and NIH activities and whether proposed executive branch changes could threaten research. Witnesses warned that cutting NIH and other research funding would harm global health progress and U.S. diplomatic interests.
The chairman closed the hearing urging legislative and executive coordination to fund global research, train clinicians in low‑resource settings and expand proven nutrition and early‑intervention programs. He thanked the witnesses and adjourned the hearing; no formal votes occurred during the session.
Ending: The hearing produced multiple policy recommendations and legislative momentum; Chairman Smith said he would pursue statutory authorization and executive‑branch measures to advance a U.S. global brain health agenda.
